ReviewCureus2024
The Impact of Maternal Graves' Disease on Neonatal Thyroid Function: A Systematic Review.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neonatal Surveillance Gaps in Maternal Graves' Disease: Findings From a Queensland Maternity Hospital.The Australian & New Zealand journal of obstetrics & gynaecology · 2026Article
- Maternal Health Risk Detection: Advancing Midwifery with Artificial Intelligence.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maternal Graves' disease (GD) poses a significant risk to neonatal thyroid function due to the transplacental transfer of thyrotropin receptor antibodies (TRAbs). This systematic review aims to assess the impact of maternal GD on neonatal thyroid outcomes and identify key maternal factors influencing these outcomes. A comprehensive literature search was conducted across PubMed, Scopus, and Cochrane, resulting in the inclusion of 18 studies published from 2014 to 2024. The review focused on neonates born to mothers with active or previous GD and investigated the effects of various maternal treatments, including antithyroid drugs (ATDs), radioactive iodine (RAI) therapy, and thyroidectomy on their offspring. The findings indicate that elevated maternal TRAb levels are a strong predictor of neonatal thyroid dysfunction, with neonates exhibiting conditions such as hyperthyroidism, transient thyrotoxicosis, or hypothyroidism. The incidence of neonatal thyroid dysfunction ranged from 0.1% to 5% in pregnancies complicated by GD, with higher rates observed in cases requiring long-term ATD therapy. Neonatal outcomes varied, with some cases resolving after appropriate treatment, while others necessitated prolonged monitoring due to risks of developmental delays and complications. The review highlights the importance of early third-trimester TRAb screening and regular neonatal thyroid function testing within the first week of life. Although neonatal outcomes were generally favorable with prompt diagnosis and treatment, the review emphasizes the need for standardized protocols to optimize monitoring and management strategies in pregnancies complicated by GD. Further research should explore long-term neurodevelopmental outcomes and evaluate the impact of different maternal treatment strategies on neonatal thyroid health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.